Patents Assigned to Aventis Pharma Deutschland GmbH
  • Publication number: 20040225013
    Abstract: The present invention relates to compounds according to the general formula (I), 1
    Type: Application
    Filed: June 3, 2004
    Publication date: November 11, 2004
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Hartmut Strobel, Paulus Wohlfart
  • Publication number: 20040225109
    Abstract: The present invention relates to a process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides of the formula I, 1
    Type: Application
    Filed: June 17, 2004
    Publication date: November 11, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Breipohl, Wolfgang Holla, Heiner Jendralla, Gerhard Beck
  • Patent number: 6815440
    Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: November 9, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase, Eckart Bartnik, Klaus-Ulrich Weithmann
  • Publication number: 20040220261
    Abstract: The invention relates to arylcycloalkyl-substituted derivatives and to their physiologically acceptable salts and physiologically functional derivatives.
    Type: Application
    Filed: February 27, 2004
    Publication date: November 4, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Christian Stapper, Heiner Glombik, Eugen Falk, Dirk Gretzke, Jochen Goerlitzer, Stefanie Keil, Hans-Ludwig Schaefer, Wolfgang Wendler
  • Publication number: 20040220148
    Abstract: Compounds of the formula I 1
    Type: Application
    Filed: October 24, 2003
    Publication date: November 4, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Hans Ulrich Stilz, Volkman Wehner, Jochen Knolle, Eckart Bartnik, Christoph Huels
  • Publication number: 20040220191
    Abstract: The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof.
    Type: Application
    Filed: February 17, 2004
    Publication date: November 4, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Lothar Schwink, Siegfried Stengelin, Matthias Gossel, Thomas Boehme, Gerhard Hessler, Petra Stahl, Dirk Gretzke
  • Patent number: 6812256
    Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: November 2, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Patent number: 6812250
    Abstract: The invention relates to carboxamide-substituted phenylurea derivatives and their physiologically tolerated salts and physiologically functional derivatives. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and process for their preparation are described. The compounds are suitable, for example, for treating type II diabetes.
    Type: Grant
    Filed: May 24, 2002
    Date of Patent: November 2, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Elisabeth Defossa, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Erich von Roedern, Stefan Peukert, Alfons Enhsen, Armin Bauer, Bernd Neises, Karl Ulrich Wendt
  • Patent number: 6812253
    Abstract: The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I) to the said mammal.
    Type: Grant
    Filed: July 22, 2003
    Date of Patent: November 2, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Paulus Wohlfart, Teri Suzuki, Ramalinga M. Dharanipragada, Alena Safarova, Armin Walser, Hartmut Strobel
  • Patent number: 6812257
    Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: November 2, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
  • Publication number: 20040214820
    Abstract: The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.
    Type: Application
    Filed: December 31, 2003
    Publication date: October 28, 2004
    Applicant: AVENTIS PHARMA DEUTSCHLAND GmbH
    Inventors: Heinz-Werner Kleemann, Jean-Christophe Carry, Pascal Desmazeau, Serge Mignani, Jean Bouoquerel, Arielle Genevois-Borella, Baptiste Ronan
  • Patent number: 6809177
    Abstract: The invention relates to a process for the conversion of echinocandin class of peptides to their C4-homotyrosine monodeoxy analogues, particularly mulundocandin to deoxymulundocandin, which consists of a single step selective reduction of C4-htyr (homotyrosine) hydroxyl group of echinocandins to their monodeoxy analogues under neutral conditions without prior protection/deprotection of the equally facile C5-Orn (ornithine) hydroxyl group and purification of the monodeoxy compound from the crude reaction mixture.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: October 26, 2004
    Assignee: Aventis Pharma Deutschland GmbH.
    Inventors: Triptikumar Mukhopadhyay, Kenia Jayvanti, Erra Koteswara Satya Vijaya Kumar
  • Patent number: 6809089
    Abstract: The present invention relates to compounds of the formula I in which A1, A2, R2 and R3 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention relates to the use of compounds of the formula I for the therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, novel compounds of the formula I, pharmaceutical preparations comprising them and processes for their preparation.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: October 26, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schindler, Karl Schoenafinger, Hartmut Strobel
  • Publication number: 20040209873
    Abstract: Arylcycloalkyl derivatives having branched side chains, processes for their preparation and their use as pharmaceuticals
    Type: Application
    Filed: February 27, 2004
    Publication date: October 21, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Christian Stapper, Heiner Glombik, Eugen Falk, Jochen Goerlitzer, Dirk Gretzke, Stefanie Keil, Hans-Ludwig Schaefer, Wolfgang Wendler
  • Publication number: 20040209931
    Abstract: Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives
    Type: Application
    Filed: February 27, 2004
    Publication date: October 21, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Wolfgang Holla, Stefanie Keil
  • Publication number: 20040210061
    Abstract: The present invention provides various processes for the preparation of (R)-&agr;-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.
    Type: Application
    Filed: May 4, 2004
    Publication date: October 21, 2004
    Applicants: Aventis Pharmaceuticals Inc., Aventis Pharma Deutschland GmbH
    Inventors: Thomas Heinz Eduard Hilpert, Hans-Wolfram Flemming, Sandra K. Stolz-Dunn, Jonathan C. Evans, Ian A. Tomlinson
  • Publication number: 20040209920
    Abstract: Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
    Type: Application
    Filed: February 27, 2004
    Publication date: October 21, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Christian Stapper, Stefanie Keil, Heiner Glombik, Eugen Falk, Jochen Goerlitzer, Dirk Gretzke, Hans-Ludwig Schaefer, Wolfgang Wendler
  • Publication number: 20040209932
    Abstract: The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives.
    Type: Application
    Filed: February 27, 2004
    Publication date: October 21, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Jochen Goerlitzer, Heiner Glombik, Eugen Falk, Dirk Gretzke, Stefanie Keil, Hans-Ludwig Schaefer, Christian Stapper, Wolfgang Wendler
  • Publication number: 20040209868
    Abstract: Compounds of the formula I 1
    Type: Application
    Filed: May 11, 2004
    Publication date: October 21, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Olaf Ritzeler, Hans Ulrich Stilz, Bernhard Neises, Gerhard Jaehne, Jorg Habermann
  • Publication number: 20040204462
    Abstract: Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals
    Type: Application
    Filed: February 27, 2004
    Publication date: October 14, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Jochen Goerlitzer, Heiner Glombik, Eugen Falk, Dirk Gretzke, Stefanie Keil, Hans-Ludwig Schaefer, Christian Stapper, Wolfgang Wendler